G Biosciences

G Biosciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.2M

Overview

G-Biosciences is a privately held, revenue-generating provider of research reagents and custom manufacturing services, primarily targeting the proteomics and broader life sciences research markets. With over 25,000 citations for its products and ISO 13485:2016 certification, it has established credibility in research and diagnostic development support. The company's business model combines the sale of catalog products (like kits, buffers, and antibodies) with high-margin custom contract manufacturing and private-label services for other biotech firms. Its integrated approach as a one-stop shop for research tools and cGMP manufacturing presents a stable, though competitive, market position.

Diagnostics

Technology Platform

Integrated portfolio of protein chemistry, purification, assay development, and cGMP manufacturing expertise for research reagents and diagnostic tools.

Funding History

11
Total raised:$5.2M
Grant$1.4M
Grant$110K
Grant$1.3M
Grant$300K

Opportunities

Growth in the diagnostic CDMO market driven by outsourcing trends, supported by its ISO 13485:2016 certification.
Increasing demand for specialized proteomics and genomics research tools from both academia and the biopharma industry.
Expansion of its private-label and custom manufacturing services as a higher-margin revenue stream.

Risk Factors

Intense competition from large, diversified life science reagent suppliers with greater resources.
Sensitivity to reductions in global research and development funding.
Execution risks associated with scaling its contract manufacturing services and maintaining stringent quality control.

Competitive Landscape

Operates in a crowded market dominated by giants like Thermo Fisher, Merck, and Bio-Rad. Competes by offering specialized, high-quality proteomics tools, a broad but integrated catalog, and value-added cGMP manufacturing services that larger players may not provide as flexibly. Faces additional competition from other specialized reagent vendors and CDMOs.